المؤلفون: Kathleen N. Moore, Alexandra Leary, Dominique Berton, Christina P. Opperman, Maria Del Pilar Estevez-Diz, Laurence Gladieff, Marek Ancukiewicz, Anne-Claire Hardy-Bessard, Frédéric Selle, Isabelle Ray-Coquard, Waldo Ortuzar Feliu, Carlos Rojas, Bradley J. Monk, David M. O'Malley, Ana Oaknin, Carla Rameri Alexandre Silva de Azevedo, Leslie M Randall, Jérôme Alexandre

المساهمون: Institut Català de la Salut, [O'Malley DM] The Ohio State University, James Comprehensive Cancer Center, Columbus, OH, United States. [Oaknin A] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Monk BJ] Arizona Oncology (US Oncology Network), Creighton University School of Medicine, Phoenix, AZ, United States. [Selle F] Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France. [Rojas C] Centro de Investigacion Clinica, Bradford Hill, Santiago, Chile. [Gladieff L] Institut Claudius Regaud-Institut Universitaire du Cancer (IUCT)-Oncopole, Toulouse, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Adult, Diarrhea, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Uterine Cervical Neoplasms, Phases of clinical research, Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Antibodies, Monoclonal, Humanized, Gastroenterology, Drug Administration Schedule, Coll uterí - Càncer - Tractament, Internal medicine, Clinical endpoint, Humans, Medicine, Infusions, Intravenous, Adverse effect, Immune Checkpoint Inhibitors, Response Evaluation Criteria in Solid Tumors, Aged, Aged, 80 and over, Enterocolitis, Cervical cancer, business.industry, Obstetrics and Gynecology, Immunotherapy, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Oncology, Medicaments - Eficàcia, Avaluació de resultats (Assistència sanitària), Female, Neoplasm Recurrence, Local, medicine.symptom, business, neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino [ENFERMEDADES]

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::305b8fceb47334a9c726d838350b5dd9Test
https://doi.org/10.1016/j.ygyno.2021.08.018Test

المؤلفون: Seock-Ah Im, Patrick Neven, John Crown, Rosa-Maria Espadero, Noelia Martínez, Yen-Shen Lu, Jonas Bergh, Thomas Bogenrieder, J. Alejandro Pérez-Fidalgo, Peter Schmid, Guy Jerusalem, Laura Schlieker, Serafin Morales, Dennis Chin-Lun Huang, Douglas Adamson, Javier Cortes, Anthony Gonçalves, Keun Seok Lee, Marie-Paule Sablin, Aleix Prat

المساهمون: Queen Mary University of London (QMUL), Institut Curie [Paris], Karolinska University Hospital [Stockholm], Seoul National University Hospital, National Taiwan University Hospital [Taipei], Ramon & Cajal University Hospital, UZ Leuven - campus Gasthuisberg, Hospital of National Cancer Center [Goyang], Hospital Universitario Arnau de Vilanova de Lleida, Biomedical Research Institute [Valencia, Spain] (INCLIVA ), Ninewells Hospital and Medical School [Dundee], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centre Hospitalier Universitaire de Liège (CHU-Liège), Boehringer Ingelheim Pharma GmbH & Co. KG, St Vincent's University Hospital, Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Institute of Oncology Prof. Dr. Alexandru Trestioreanu (IOB), Institut Català de la Salut, [Schmid P] Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. [Sablin MP] Department of Drug Development and Innovation, Institut Curie, Paris, France. [Bergh J] Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden. [Im SA] Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. [Lu YS] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. [Martínez N] Department of Oncology, Ramon y Cajal University Hospital, Madrid, Spain. [Cortés J] Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Oncology, IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Breast Cancer Research
Breast Cancer Research, 2021, 23 (1), pp.8. ⟨10.1186/s13058-020-01382-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research : BCR
Scientia

مصطلحات موضوعية: Oncology, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Exemestane, Antineoplastic Combined Chemotherapy Protocols, terapéutica::farmacoterapia::farmacoterapia combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Clinical endpoint, Insulin-like growth factor, Neoplasm Metastasis, Aged, 80 and over, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], 0303 health sciences, education.field_of_study, Hazard ratio, Therapeutics::Drug Therapy::Drug Therapy, Combination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Disease Management, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Metastatic breast cancer, Treatment Outcome, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Receptors, Progesterone, Life Sciences & Biomedicine, Research Article, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Population, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Hormone receptor-positive, Humans, Xentuzumab, Everolimus, education, Adverse effect, Aged, Neoplasm Staging, 030304 developmental biology, Science & Technology, business.industry, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Androstadienes, chemistry, Mama - Càncer - Tractament, Medicaments - Eficàcia, business, HER2-negative

وصف الملف: application/pdf; Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fb312f1fe2cc964111c140ba48f774Test
https://hal.science/hal-03630009Test

المؤلفون: Lorena Fariñas-Madrid, Angel Guerrero-Zotano, Raquel López-Reig, Pedro Mallol, Victor Rodriguez-Freixinos, Ana Oaknin, Andres Poveda, Ignacio A. Romero, José Antonio López-Guerrero

المساهمون: Institut Català de la Salut, [Poveda A] Oncogynecologic Department, Initia Oncology, Hospital Quironsalud Valencia, Avda Blasco Ibañez, 14, 46 010 Valencia, Spain. [Oaknin A, Fariñas-Madrid L] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Romero I, Guerrero-Zotano A] Department of Medical Oncology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain. [Rodriguez-Freixinos V] Department of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientific Reports
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
instname
r-CIPF: Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Centro de Investigación Principe Felipe (CIPF)
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientia

مصطلحات موضوعية: 0301 basic medicine, Oncology, Molecular biology, Piperazines, Medicaments antineoplàstics, chemistry.chemical_compound, 0302 clinical medicine, Neoplasms, terapéutica::farmacoterapia::farmacoterapia combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Càncer, Cancer, Multidisciplinary, Therapeutics::Drug Therapy::Drug Therapy, Combination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Middle Aged, 030220 oncology & carcinogenesis, Vomiting, Medicine, medicine.symptom, medicine.medical_specialty, Genotype, Maximum Tolerated Dose, Nausea, Anemia, Science, Neutropenia, Poly(ADP-ribose) Polymerase Inhibitors, Heterocyclic Compounds, 4 or More Rings, Article, Olaparib, neoplasias [ENFERMEDADES], 03 medical and health sciences, Breast cancer, Medical research, Pharmacokinetics, Internal medicine, medicine, Humans, Adverse effect, Aged, business.industry, medicine.disease, Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Drug [PHENOMENA AND PROCESSES], Neoplasms [DISEASES], 030104 developmental biology, chemistry, Medicaments - Eficàcia, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::relación dosis-respuesta de medicamentos [FENÓMENOS Y PROCESOS], Phthalazines, business, Carbolines

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a11dd091df1dfd415fa0f313d9b3f47Test
https://pubmed.ncbi.nlm.nih.gov/33627685Test